R1	Has_value Arg1:T5 Arg2:T4	
*	OR T2 T3
*	OR T10 T11
R2	Has_qualifier Arg1:T9 Arg2:T10	
*	OR T6 T7
R3	Has_value Arg1:T6 Arg2:T8	
R4	AND Arg1:T9 Arg2:T6	
R5	Has_value Arg1:T15 Arg2:T16	
*	OR T18 T17
R6	AND Arg1:T18 Arg2:T19	
*	OR T22 T23 T24
R7	AND Arg1:T22 Arg2:T25	
R8	Has_qualifier Arg1:T22 Arg2:T21	
R9	AND Arg1:T28 Arg2:T29	
*	OR T33 T34
R10	Has_temporal Arg1:T30 Arg2:T31	
R11	AND Arg1:T30 Arg2:T33	
R12	Has_index Arg1:T37 Arg2:T38	
R13	Has_temporal Arg1:T36 Arg2:T37	
*	OR T27 T28 T30
R14	Subsumes Arg1:T21 Arg2:T27	
R15	Has_value Arg1:T40 Arg2:T41	
R16	Has_value Arg1:T42 Arg2:T43	
R17	Has_value Arg1:T44 Arg2:T45	
*	OR T40 T42 T44
R18	Has_value Arg1:T46 Arg2:T47	
R19	Has_value Arg1:T48 Arg2:T49	
R20	Has_value Arg1:T50 Arg2:T51	
R21	Has_value Arg1:T52 Arg2:T53	
R22	Has_value Arg1:T54 Arg2:T55	
R23	Has_value Arg1:T56 Arg2:T57	
R24	Has_value Arg1:T58 Arg2:T59	
R25	Has_index Arg1:T31 Arg2:T32	
T1	Post-eligibility 0 85	Subject or subject's legally acceptable representative has provided informed consent.
T2	Person 87 91	Male
T3	Person 95 101	female
T4	Value 102 112	>=18 years
T5	Person 116 119	age
T6	Procedure 122 136	Histologically
T7	Procedure 140 153	cytologically
T8	Value 154 163	confirmed
T9	Condition 177 191	adenocarcinoma
T10	Qualifier 199 204	colon
T11	Qualifier 208 214	rectum
T14	Non-query-able 217 480	Wild-type KRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) and wild-type NRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) tumor status.
T15	Measurement 482 542	Eastern Cooperative Oncology Group (ECOG) performance status
T16	Value 546 555	0, 1 or 2
T17	Condition 572 594	non-measurable disease
T18	Condition 558 568;587 594	Measurable disease
T19	Procedure 599 617	RECIST Version 1.1
T21	Qualifier 630 636	failed
T22	Procedure 643 660;691 714	fluoropyrimidine- containing chemotherapy
T23	Procedure 662 674;691 714	oxaliplatin- containing chemotherapy
T24	Procedure 680 714	irinotecan-containing chemotherapy
T25	Condition 728 746	metastatic disease
T27	Condition 777 796	disease progression
T28	Condition 827 838	intolerance
T29	Procedure 842 853	the regimen
T30	Condition 855 873	Metastatic relapse
T31	Temporal 874 928	within 6 months after completing adjuvant chemotherapy
T32	Reference_point 890 928	after completing adjuvant chemotherapy
T33	Procedure 945 955;971 989	irinotecan containing regimen
T34	Procedure 959 989	oxaliplatin containing regimen
T36	Condition 1091 1123	Adequate baseline organ function
T37	Temporal 1136 1183	<=7 days prior to first dose of study treatment
T38	Reference_point 1154 1183	first dose of study treatment
T40	Measurement 1221 1252	Absolute neutrophil count (ANC)
T41	Value 1253 1275	>=1.5 x 10^9/Liter (L)
T42	Measurement 1277 1291	Platelet count
T43	Value 1292 1305	>=75 x 10^9/L
T44	Measurement 1307 1317	Hemoglobin
T45	Value 1318 1345	>=8.0 gram/deciliter (g/dL)
T46	Measurement 1376 1386	Creatinine
T47	Value 1387 1422	<=1.5 x upper limit of normal (ULN)
T48	Measurement 1456 1487	spartate aminotransferase (AST)
T49	Value 1488 1497	<=3 x ULN
T50	Measurement 1499 1529	Alanine aminotransferase (ALT)
T51	Value 1530 1539	<=3 x ULN
T52	Measurement 1541 1556	Total Bilirubin
T53	Value 1557 1568	<=1.5 x ULN
T54	Measurement 1603 1618	Serum Magnesium
T55	Value 1619 1639	within normal limits
T56	Measurement 1641 1654	Serum Calcium
T57	Value 1655 1675	within normal limits
T58	Measurement 1677 1692	Serum Potassium
T59	Value 1693 1713	within normal limits
T60	Pregnancy_considerations 1861 2324	Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use adequate contraception, during the study and for 2 months following the last dose of study treatment. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use adequate contraception, from time of signing informed consent until 5 months after the last dose of study treatment.
T61	Non-query-able 1716 1859	All prior treatment related toxicities common terminology criteria for adverse events (CTCAE) version 4.03 <=Grade 1 at the time of enrollment.
